Interpreting DeLLphi-301 Trial Results: ORR, Duration of Response, and Long-Term Outcomes

Joshua K. Sabari, MD, discusses how the ORR of 32% to 40% observed in the DeLLphi-301 clinical trial among participants receiving tarlatamab is clinically meaningful, particularly given that these responses occurred between 5 and 7 weeks after initiation and emphasize the importance of ORR as a primary end point in evaluating the efficacy of treatment in this patient population.

EP: 1.Clinical Impressions and Therapy Goals

EP: 2.Considerations for Extended Chemoimmunotherapy

EP: 3.Prophylactic Cranial Irradiation Considerations

EP: 4.Mechanism of Action of BiTE Immunotherapy

Now Viewing

EP: 5.Interpreting DeLLphi-301 Trial Results: ORR, Duration of Response, and Long-Term Outcomes

EP: 6.Significance of Durable Responses in DeLLphi-301 Trial

EP: 7.Expectations for PFS and OS in Relapsed/Refractory SCLC

EP: 8.Future Potential in Combination Therapies

EP: 9.Dual Maintenance With BiTE and PD-L1 Inhibitors

EP: 10.B7-H3 Mechanism and Therapeutic Potential

EP: 11.Current Practices in B7-H3 Testing

EP: 12.Interpreting IDeate-Lung02 Trial Outcomes

EP: 13.Comparing Dosing Schedules With Standard Therapies

EP: 14.Potential Synergies With T-Cell Engagers

EP: 15.Prospects in First-Line and Maintenance Settings

EP: 16.Mechanism of Action Compared With Other Alkylating Agents

EP: 17.Efficacy in Platinum-Sensitive vs Platinum-Resistant SCLC

EP: 18.Comparative Efficacy and Future Directions in SCLC Treatment

Video content above is prompted by the following:

Please provide your insights on an ORR of 32% to 40% among participants in the 10-mg and 100-mg groups of the DeLLphi-301 clinical trial.

• How clinically meaningful is an objective response observed between 5 and 7 weeks of tarlatamab initiation?
• Please express your views on selecting ORR as the primary end point in this study.

Recent Videos